Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy by Matteo Bolcato, Claudio Jommi

Connect to this object online.

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi

Connect to this object online.

Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy by Monica Hildegard Otto, Monica Hildegard Otto, Carla Pillarella, Claudio Jommi, Claudio Jommi

Connect to this object online.

Current pipelines for neglected diseases. by Paolo di Procolo, Claudio Jommi

Connect to this object online.

The economic impact of compassionate use of medicines by Claudio Jommi, Federico Pantellini, Lisa Stagi, Maria Verykiou, Marianna Cavazza

Connect to this object online.

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? by Virginia Ronco, Myriam Dilecce, Elena Lanati, Pier Luigi Canonico, Claudio Jommi

Connect to this object online.

Vitiligo: Unmet Need, Management and Treatment Guidelines by Angelo Valerio Marzano, Silvia Alberti-Violetti, Carlo Alberto Maronese, Gianluca Avallone, Claudio Jommi

Connect to this object online.

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case by Alice Tarantola, Monica Hildegard Otto, Patrizio Armeni, Francesco Costa, Francesco Malandrini, Claudio Jommi

Connect to this object online.

Content validity of the EQ-HWB and EQ-HWB-S in a sample of Italian patients, informal caregivers and members of the general public by Sara Masutti, Camilla Falivena, Fredrick Dermawan Purba, Claudio Jommi, Clara Mukuria, Aureliano Paolo Finch

Connect to this object online.

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions by Claudio Jommi, Stefania Bramanti, Marcello Pani, Alessandro Ghirardini, Alessandro Ghirardini, Armando Santoro, Armando Santoro

Connect to this object online.

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? by Michael Drummond, Oriana Ciani, Giulia Fornaro, Claudio Jommi, Eva Susanne Dietrich, Jaime Espin, Jean Mossman, Gerard de Pouvourville

Connect to this object online.

A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results by Roberta Joppi, Elisa Cinconze, Luca Demattè, Renato Guseo, Claudio Jommi, Cinzia Mortarino, Daniela Pase, Chiara Poggiani, Alessandro Roggeri, Daniela Roggeri

Connect to this object online.

Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study by Maria Caterina Cavallo, Marianna Cavazza, Francesca Bonifazi, Beatrice Casadei, Ilaria Cutini, Barbara Tonietti, Riccardo Saccardi, PierLuigi Zinzani, Claudio Jommi

Connect to this object online.

Unlocking the potential of established products: toward new incentives rewarding innovation in Europe by Gabrielle Nayroles, Sandrine Frybourg, Sylvie Gabriel, Åsa Kornfeld, Fernando Antoñanzas-Villar, Jaime Espín, Claudio Jommi, Nello Martini, Gérard de Pouvourville, Keith Tolley, Jürgen Wasem, Mondher Toumi

Connect to this object online.

Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmoniz... by Lucia Gozzo, Kenneth Paterson, Olivier Wong, Francis Megerlin, Jan Geldmacher, Patrizia Popoli, Claudio Jommi, Frank-Ulrich Fricke, Oriol De Solà-Morales, Isao Kamae, Guido Rasi, Filippo Drago, Filippo Drago, Filippo Drago

Connect to this object online.